StockMacro
Menu

Dianthus Therapeutics

$84.55 -2.6% in 6 monthsMarket cap $4.8B

DNTH on XNAS, Health Care, Dianthus Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares rose 109% in a year while insiders sold $15.7M in 90 days and the 12-month loss was $202.1M.

  • BadShort interest at 16% of shares, up 3.2% from the prior report

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Industry
Pharmaceutical preparations (Health Care)
Employees
92
Website
dianthustx.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $46.6M.
Quarter to 31 Dec 2021: revenue –, net income -$19.3MQuarter to 31 Mar 2022: revenue –, net income -$22.9MQuarter to 30 Jun 2022: revenue –, net income -$17.3MQuarter to 30 Sep 2022: revenue $1.2M, net income -$16.1MQuarter to 30 Sep 2022: revenue $1.2M, net income -$16.1MQuarter to 31 Dec 2022: revenue –, net income -$20.2MQuarter to 31 Mar 2023: revenue –, net income -$29.2MQuarter to 30 Jun 2023: revenue –, net income -$3.3MQuarter to 30 Sep 2023: revenue $924K, net income -$14.8MQuarter to 30 Sep 2023: revenue $924K, net income -$14.8MQuarter to 31 Dec 2023: revenue $457K, net income –Quarter to 31 Mar 2024: revenue $874K, net income -$13.7MQuarter to 31 Mar 2024: revenue $874K, net income -$13.7MQuarter to 30 Jun 2024: revenue $1.9M, net income -$17.6MQuarter to 30 Jun 2024: revenue $1.9M, net income -$17.6MQuarter to 30 Sep 2024: revenue $2.2M, net income -$25.2MQuarter to 30 Sep 2024: revenue $2.2M, net income -$25.2MQuarter to 31 Dec 2024: revenue $1.3M, net income -$28.4MQuarter to 31 Dec 2024: revenue $1.3M, net income -$28.4MQuarter to 31 Mar 2025: revenue $1.2M, net income -$29.5MQuarter to 31 Mar 2025: revenue $1.2M, net income -$29.5MQuarter to 30 Jun 2025: revenue $193K, net income -$31.6MQuarter to 30 Jun 2025: revenue $193K, net income -$31.6MQuarter to 30 Sep 2025: revenue $396K, net income -$36.8MQuarter to 30 Sep 2025: revenue $396K, net income -$36.8MQuarter to 31 Dec 2025: revenue $284K, net income -$64.4MQuarter to 31 Dec 2025: revenue $284K, net income -$64.4MQuarter to 31 Mar 2026: revenue –, net income -$40.8MQuarter to 30 Jun 2026: revenue –, net income -$50.2MQuarter to 30 Sep 2026: revenue –, net income -$46.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $64.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$46.6M
30 Jun 2026–-$50.2M
31 Mar 2026–-$40.8M
31 Dec 2025$284K-$64.4M
30 Sep 2025$396K-$36.8M
30 Jun 2025$193K-$31.6M
31 Mar 2025$1.2M-$29.5M
31 Dec 2024$1.3M-$28.4M
30 Sep 2024$2.2M-$25.2M
30 Jun 2024$1.9M-$17.6M
31 Mar 2024$874K-$13.7M
31 Dec 2023$457K–
30 Sep 2023$924K-$14.8M
30 Jun 2023–-$3.3M
31 Mar 2023–-$29.2M
31 Dec 2022–-$20.2M
30 Sep 2022$1.2M-$16.1M
30 Jun 2022–-$17.3M
31 Mar 2022–-$22.9M
31 Dec 2021–-$19.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – $3.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$202.1M -$126.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$4.08 -$3.49
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -22.6% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$109.6M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $837.8M $402.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$837.8M (net cash) -$402.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $22.05
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.8 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Dianthus TherapeuticsDNTH (this company) $4.8Bloss–––
ErascaERAS $4.8Bloss–––
PTC TherapeuticsPTCT $4.7Bloss4.1-35%-9.2%
Cogent BiosciencesCOGT $4.6Bloss–––
LiquidiaLQDA $4.9Bloss7.9+798%-15.1%
Travere TherapeuticsTVTX $4.5Bloss6.9+49%-18.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$15.7M

bought $0, sold $15.7M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.0%

272 13F filers vs 264

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

67.4M shares held by 13F filers (30 Sep 2026) of 56.3M outstanding (2 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

16%

9.3M shares sold short (30 Oct 2026) of 56.3M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.1

9.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.2%

9.0M shares sold short in the report before, 9.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

73%

73% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

13

13 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.5×

13 articles in the last 7 days; its usual week has 2.

Price $84.55 on 20 Nov 2026, +109% over 12 months (12-month range $36.20 to $115.96)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $75.1M in the last 12 months (the 12 months before: -$8.1M).
Revenue per quarter. Revenue $284K in the latest quarter, -79% on a year earlier.
Capital spending per quarter. Capital spending $368K in the latest quarter, +7260% on a year earlier.
Institutional holders (13F filers). 272 13F filers reported holding it in the latest 13F quarter, +97% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 87 vs usual 23.50 (2026-03-31); 5.8x the same period a year earlier
22 May 20258-K and other filingsDirector or officer change
5 Mar 20258-K and other filingsDirector or officer change
5 Mar 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Sep 20248-K and other filingsDirector or officer change
16 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 20248-K and other filingsDirector or officer change
28 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Mar 20248-K and other filingsRegistered new securities for sale (S-1)
7 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
21 Dec 20238-K and other filingsRegistered new securities for sale (S-1)
25 Oct 20238-K and other filingsChanged its auditor
12 Sep 20238-K and other filingsDirector or officer change
12 Sep 20238-K and other filingsChanged its auditor
12 Sep 20238-K and other filingsCompleted an acquisition or asset sale
12 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 20238-K and other filingsDirector or officer change
3 May 20238-K and other filingsDirector or officer change
6 Apr 20238-K and other filingsA major agreement ended
7 Feb 20238-K and other filingsDirector or officer change
7 Feb 20238-K and other filingsRestructuring costs announced
7 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Feb 20238-K and other filingsDelisting notice or listing transfer
17 Aug 20228-K and other filingsDirector or officer change
17 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 May 20228-K and other filingsDirector or officer change
2 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2023: -$3.1M published
Month from 1 Sep 2023: $1.1M published
Month from 1 Oct 2023: $336K published
Month from 1 Sep 2025: -$700K published
Month from 1 Nov 2025: -$7.4M published
Month from 1 Dec 2025: -$904K published
Month from 1 Mar 2026: -$18.5M published
Month from 1 Apr 2026: -$10.3M published
Month from 1 May 2026: -$51K published
Month from 1 Jun 2026: -$4.8M published
Month from 1 Jul 2026: -$3.2M published
Month from 1 Aug 2026: -$21.6M published
Month from 1 Sep 2026: -$4.5M published
Month from 1 Nov 2026: -$11.2M published
Revenue per quarter
Quarter ended 30 Sep 2022: $1.2M; public on 10 Nov 2023
Quarter ended 30 Sep 2023: $924K, -21% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $457K; public on 12 Mar 2025
Quarter ended 31 Mar 2024: $874K; public on 13 May 2025
Quarter ended 30 Jun 2024: $1.9M; public on 8 Aug 2025
Quarter ended 30 Sep 2024: $2.2M, +135% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2024: $1.3M, +190% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $1.2M, +33% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $193K, -90% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $396K, -82% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $284K, -79% on a year earlier; public on 10 Mar 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $15K, -93% on a year earlier; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $27K, +286% on a year earlier; public on 17 May 2022
Quarter ended 30 Jun 2022: $129K, +16% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $158K, -86% on a year earlier; public on 4 Nov 2022
Quarter ended 30 Sep 2023: $65K, -59% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $10K; public on 22 Mar 2024
Quarter ended 31 Mar 2024: $32K; public on 10 May 2024
Quarter ended 30 Jun 2024: $17K; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $25K, -62% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $31K, +210% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $24K, -25% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $46K, +171% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $5K, -80% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $138K, +345% on a year earlier; public on 10 Mar 2026
Quarter ended 31 Mar 2026: $10K, -58% on a year earlier; public on 6 May 2026
Quarter ended 30 Sep 2026: $368K, +7260% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
30 Sep 2023 report: 29; public on 14 Nov 2023
31 Dec 2023 report: 37; public on 14 Feb 2024
31 Mar 2024 report: 74; public on 15 May 2024
30 Jun 2024 report: 74; public on 14 Aug 2024
30 Sep 2024 report: 89; public on 14 Nov 2024
31 Dec 2024 report: 95; public on 14 Feb 2025
31 Mar 2025 report: 97; public on 15 May 2025
30 Jun 2025 report: 100; public on 14 Aug 2025
30 Sep 2025 report: 138; public on 14 Nov 2025
31 Dec 2025 report: 164; public on 17 Feb 2026
31 Mar 2026 report: 236; public on 15 May 2026
30 Jun 2026 report: 264; public on 14 Aug 2026
30 Sep 2026 report: 272; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, fiscal year at $2.0M (31 Dec 2025), higher than 71% of its own history.
  • Insider net buying (open market): Insiders sold a net $75.1M in the last 12 months (the 12 months before: -$8.1M).
  • Revenue per quarter: Revenue $284K in the latest quarter, -79% on a year earlier.
  • Capital spending per quarter: Capital spending $368K in the latest quarter, +7260% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 65 insider trades

Last 90 days: 3 sales, $15.7M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
12 Nov 2026Ryan SavitzEVP, CFO & CBOSellplanned in advance (10b5-1); after exercising options124,042$90.52$11.2MForm 4
18 Sep 2026Edward CarrCHIEF ACCOUNTING OFFICERSellplanned in advance (10b5-1); after exercising options20,000$101.38$2.0MForm 4
3 Sep 2026Simrat RandhawaEVP, Head of R&DSellplanned in advance (10b5-1); after exercising options23,124$106.41$2.5MForm 4
19 Aug 2026Simon ReadDirectorSellplanned in advance (10b5-1); after exercising options2,778$117.55$327KForm 4
11 Aug 2026Anne McGeorgeDirectorSellplanned in advance (10b5-1); after exercising options7,750$109.01$845KForm 4
11 Aug 2026Adam M VenessSVP, General Counsel and Sec.Sellplanned in advance (10b5-1); after exercising options20,000$110.44$2.2MForm 4
11 Aug 2026Simon ReadDirectorSellplanned in advance (10b5-1); after exercising options2,777$109.55$304KForm 4
7 Aug 2026Marino GarciaCEO AND PRESIDENTSellplanned in advance (10b5-1); after exercising options166,000$108.11$17.9MForm 4

272 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 38 opened a position, 34 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)8.6M15.2%$753.1M+353K+4.3%
T. Rowe Price Investment Management, Inc.5.9M10.5%+2.0M+51%
BlackRock, Inc.4.4M7.80%$386.5M+266K+6.4%
Wellington Management Group LLP3.0M5.34%$264.7M-224K-6.9%
Fairmount Funds Management LLC2.5M4.51%$223.4MNo change
State Street Corp2.5M4.50%$223.1M+177K+7.5%
Vanguard Capital Management LLC2.4M4.31%$213.8M+269K+12%
T. Rowe Price Associates Inc2.2M3.92%-307K-12%
Avidity Partners Management LP1.9M3.37%$167.3M-205K-9.7%
Octagon Capital Advisors LP1.7M3.00%$148.5M-155K-8.4%

Company events

All 50 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
12 Mar 2026Signed a major agreement8-K
16 Oct 2025Signed a major agreement8-K
11 Sep 2025Signed a major agreement8-K
22 May 2025Director or officer changeSame filing: shareholder vote results8-K
5 Mar 2025Director or officer change8-K
16 Sep 2024Director or officer change8-K
28 May 2024Director or officer changeSame filing: shareholder vote results8-K
21 Mar 2024Registered new securities for sale (S-1)S-1/A

The 5 newest of 102 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 15 May 2026Institutional holdings change

    saw 87 13F filers open a new position in the quarter ended 31 Mar 2026, 5.8× the same quarter last year.

    Same quarter last year: 15; its normal quarter is 23.5.

    See the evidence
    This period
    87 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    23.5
    Typical spread (median absolute deviation)
    11.5
    How far from its usual level
    +3.7
    Same quarter last year
    15
    History used
    913 days
    2024-03-31: 382024-06-30: 252024-09-30: 222024-12-31: 82025-03-31: 152025-06-30: 182025-09-30: 512025-12-31: 402026-03-31: 87
    the quarter ended 31 Mar 20268 earlier quartersnormal: 23.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  2. 22 May 2025Filings record

    Director or officer change

  3. 5 Mar 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 5 Mar 2025Filings record

    Director or officer change

  5. 16 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 16 Sep 2024Filings record

    Director or officer change

  7. 28 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 28 May 2024Filings record

    Director or officer change

  9. 21 Mar 2024Filings record

    Registered new securities for sale (S-1)

  10. 7 Feb 2024Filings record

    Registered new securities for sale (S-1)

  11. 21 Dec 2023Filings record

    Registered new securities for sale (S-1)

  12. 25 Oct 2023Filings record

    Changed its auditor

  13. 4 Oct 2023Insiders record

    Harwin Peter Evan (director) and 2 other(s) bought 24,670 shares of DNTH ($336,252) (dated 3 Oct 2023)

  14. 29 Sep 2023Insiders record

    Kiselak Tomas (director) and 2 other(s) bought 30,000 shares of DNTH ($394,500) (dated 28 Sep 2023)

  15. 26 Sep 2023Insiders record

    Randhawa Simrat (Chief Medical Officer) bought 4,000 shares of DNTH ($52,800) (dated 25 Sep 2023)

  16. 22 Sep 2023Insiders record

    Kiselak Tomas (director) and 2 other(s) bought 30,000 shares of DNTH ($396,000) (dated 21 Sep 2023)

  17. 14 Sep 2023Insiders record

    Kiselak Tomas (director) and 2 other(s) bought 24,254 shares of DNTH ($271,680) (dated 13 Sep 2023)

  18. 12 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 12 Sep 2023Filings record

    Director or officer change

  20. 12 Sep 2023Filings record

    Changed its auditor

  21. 12 Sep 2023Filings record

    Completed an acquisition or asset sale

  22. 19 May 2023Filings record

    Director or officer change

  23. 3 May 2023Filings record

    Director or officer change

  24. 6 Apr 2023Filings record

    A major agreement ended

  25. 7 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 7 Feb 2023Filings record

    Director or officer change

  27. 7 Feb 2023Filings record

    Restructuring costs announced

  28. 2 Feb 2023Filings record

    Delisting notice or listing transfer

  29. 17 Aug 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 17 Aug 2022Filings record

    Director or officer change

  31. 2 May 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 2 May 2022Filings record

    Director or officer change

  33. 5 Aug 2021Filings record

    Director or officer change

  34. 7 Jun 2021Filings record

    Director or officer change

  35. 27 May 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 27 May 2021Filings record

    Director or officer change

  37. 23 Dec 2020Filings record

    Director or officer change

  38. 9 Nov 2020Filings record

    Director or officer change

  39. 2 Oct 2020Filings record

    Director or officer change

  40. 2 Sep 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 58 entries; narrow the window or the kind of data to see older ones.

Not listed: 163 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001690585
Ticker
DNTH
Domain
dianthustx.com
Hq location
NY|NEW YORK|10036 (1 unverified)
Name
Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc.
Wikidata
Q99744291
  • SEC Form 13F institutional holdings117 data points30 Sep 2023 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)144 records23 Nov 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)577 data points31 Dec 2015 to 2 Nov 2026
  • SEC Form 4 insider transactions65 records, 180 data points27 Jun 2018 to 12 Nov 2026
  • FINRA short interest (twice monthly)228 data points15 Sep 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1606 data points12 Sep 2023 to 20 Nov 2026